Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets

Thrombosis and Haemostasis

Volumn 111, Issue 6, 2014, Pages 1184-1186

  Wang, Hong ^a   Annie Bang, K W ^b   Blanchette, Victor S ^c,d   Nurden, Alan T ^e   Rand, Margaret L ^a,c,f  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Ctr Geriatrie Ctr Hosp Univ B   (France)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; GLYCOPROTEIN IIB; PHOSPHATIDYLSERINE; THROMBIN; ALPHA2 INTEGRIN; FIBRINOGEN RECEPTOR; ITGA2B PROTEIN, HUMAN;

CASE REPORT; CONTROLLED STUDY; DEPOLARIZATION; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; FRAMESHIFT MUTATION; GLANZMANN DISEASE; HUMAN; HUMAN CELL; LETTER; MEMBRANE MICROPARTICLE; MITOCHONDRIAL DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; BLOOD; CASE CONTROL STUDY; CHILD; GENETICS; METABOLISM; MUTATION; PATHOLOGY; THROMBOCYTE;

BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; CHILD; HUMANS; INTEGRIN ALPHA2; MEMBRANE POTENTIAL, MITOCHONDRIAL; MUTATION; PHOSPHATIDYLSERINES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBASTHENIA; THROMBIN;

EID: 84901951856     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-08-0704     Document Type: Letter

References (21)

1. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Rev Hematol 2012; 5: 487-503.
2. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-874.
3. Beguin S, Kumar R, Keularts I, et al. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-570.
4. Dargaud Y, Bordet JC, Trzeciak MC, et al. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica 2006; 91: 17-20.
5. Keuren JF, Ulrichts H, Feijge MA, et al. Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma. J Lab Clin Med 2003; 141: 350-358.
6. Bevers EM, Comfurius P, Nieuwenhuis HK, et al. Platelet prothrombin converting activity in hereditary disorders of platelet function. Br J Haematol 1986; 63: 335-345.
7. Weiss HJ, Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome. Blood 1997; 89: 1599-1611.
8. Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem 1993; 268: 14586-14589.
9. Holme PA, Solum NO, Brosstad F, et al. Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa. Thromb Haemost 1995; 74: 1533-1540.
10. van der Meijden PE, Feijge MA, Swieringa F, et al. Key role of integrin alpha(IIb)beta (3) signaling to Syk kinase in tissue factor-induced thrombin generation. Cell Mol Life Sci 2012; 69: 3481-3492.
11. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 2009; 35: 233-241.
12. Lages B, Weiss HJ. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors. Br J Haematol 2001; 113: 65-71.
13. Goto S, Tamura N, Li M, et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-2030.
14. Rand ML, Wang H, Bang KW, et al. Phosphatidylserine exposure and other apoptotic-like events in Bernard-Soulier syndrome platelets. Am J Hematol 2010; 85: 584-592.
15. Shadle PJ, Ginsberg MH, Plow EF, et al. Plateletcollagen adhesion: inhibition by a monoclonal antibody that binds glycoprotein IIb. J Cell Biol 1984; 99: 2056-2060.
16. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11: 2-16.
17. Rand ML, Wang H, Bang KW, et al. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steadystate senescence. J Thromb Haemost 2004; 2: 651-659.
18. Leung R, Gwozdz AM, Wang H, et al. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. J Thromb Haemost 2007; 5: 560-570.
19. Gwozdz AM, Leung R, Wang H, et al. Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects. Thromb Haemost 2010; 103: 1218-1227.
20. van Kruchten R, Mattheij NJ, Saunders C, et al. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood 2013; 121: 1850-1857.
21. Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry: from the characterisation of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb Haemost 2011; 9: 1883-1891.